Cargando…
Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
Anthracyclines constitute the backbone of intensive adult acute myeloid leukemia (AML) therapy. Cardiotoxicity is one of its most serious adverse effects, and its incidence increases with cumulative dose. Dexrazoxane is a cardioprotective agent used in conjunction with anthracycline therapy. There i...
Autores principales: | Vachhani, Pankit, Shin, Sarah, Baron, Jeffrey, Thompson, James E., Wetzler, Meir, Griffiths, Elizabeth A., Ontiveros, Evelena P., Spangenthal, Edward J., Wang, Eunice S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402627/ https://www.ncbi.nlm.nih.gov/pubmed/28462084 http://dx.doi.org/10.1016/j.lrr.2017.04.001 |
Ejemplares similares
-
Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
por: Pandey, Manu R., et al.
Publicado: (2017) -
Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response
por: Mohammadi, Fatemeh, et al.
Publicado: (2021) -
Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature
por: Vachhani, Pankit, et al.
Publicado: (2014) -
How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes
por: Sharafeldin, Noha, et al.
Publicado: (2022) -
Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)